Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending October 2012. The report details a specific share repurchase transaction executed on October 3, 2012, pursuant to shareholder authority granted at the Annual General Meeting on May 3, 2012.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on capital structure and share repurchase activity.
- Shares Purchased: 450,000 Ordinary Shares of 25 pence each.
- Purchase Price Range: Highest price paid was 1,451.5 pence per share; lowest price paid was 1,439.5 pence per share.
- Treasury Holdings (Settled): 502,615,427 shares (9.23% of total issued share capital).
- Treasury Holdings (Including Unsettled): 503,965,427 shares (10.20% of current total voting rights).
- Shares in Issue (Excluding Treasury): 4,941,803,294 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 450,000 shares for Treasury. Consequently, the percentage of total voting rights held in Treasury increased to 10.20% when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operational outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities and is made in conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (502,615,427 settled) against the company's latest capitalization table.
- Confirm the calculation of total voting rights (10.20% held in Treasury including unsettled shares).
- Check the number of shares in issue excluding Treasury (4,941,803,294) for use in disclosure threshold calculations under FSA rules.
- Note that this filing does not contain financial performance data; refer to the most recent Form 20-F or interim results for revenue and profit metrics.